2022
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
Garcia-Manero G, Mufti GJ, Fenaux P, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Ilhan O, Sekeres MA, Zeidan AM, Ito R, Zhang J, Rampersad A, Sinsimer D, Backstrom JT, Platzbecker U, Komrokji RS. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood 2022, 139: 624-629. PMID: 34758066, PMCID: PMC8796653, DOI: 10.1182/blood.2021012589.Peer-Reviewed Original Research
2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
Zeidan AM, Lee J, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Katterling RP, Tallman MS, Gore SD. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. British Journal Of Haematology 2014, 167: 62-68. PMID: 24995683, PMCID: PMC4299466, DOI: 10.1111/bjh.13008.Peer-Reviewed Original ResearchConceptsOligoblastic acute myeloid leukemiaAzacitidine therapyPrognostic scoring systemAcute myeloid leukemiaMyelodysplastic syndromePlatelet countMyeloid leukemiaScoring systemInternational Prognostic Scoring SystemProspective clinical trialsRisk of deathNorth American patientsUnmet medical needRevised IPSSObjective responsePrognostic utilityClinical benefitAmerican patientsClinical trialsDutch cohortLarge cohortSurvival advantageMolecular predictorsPatientsTop research priorities